Platelet Patents (Class 424/532)
-
Patent number: 11891620Abstract: Platelet lysate compositions and cell culture media compositions for maintaining and/or growing mammalian cells, such as mammalian endothelial cells (ECs) and mammalian endothelial progenitor cells (EPCs), in particular human ECs (huECs) and human EPCs (huEPCs), such as primary huECs and primary huEPCs, are provided. The cell culture media compositions contain a basal medium, a platelet lysate and, optionally, one or more exogenously added growth factors. Also provided are methods for making and using such cell culture media compositions to grow and/or maintain ECs and EPCs, including huECs and huEPCs, as well as cell culture vessels, dishes, plates, and/or flasks pretreated with the cell culture media compositions.Type: GrantFiled: May 14, 2015Date of Patent: February 6, 2024Assignee: Mayo Foundation for Medical Education and ResearchInventors: Allan B. Dietz, Gaylord Knutson
-
Patent number: 11464829Abstract: Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample. In certain embodiments, the growth factor release is not accompanied by clotting within the blood sample.Type: GrantFiled: July 17, 2019Date of Patent: October 11, 2022Assignee: GENERAL ELECTRIC COMPANYInventors: Vasile Bogdan Neculaes, Andrew Soliz Torres, Antonio Caiafa, Brian Dun-Lan Lee, Allen Lawrence Garner
-
Patent number: 11458113Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.Type: GrantFiled: July 7, 2019Date of Patent: October 4, 2022Assignee: Trilogic Pharma LLCInventors: Hemant H. Alur, James A H Harwick
-
Patent number: 10993965Abstract: The present disclosure is drawn to compositions and methods of making and using lyophilized platelet lysates. Specifically, a method of preparing a composition suitable for therapeutic use or as a culture medium can comprise steps of concentrating platelets from a platelet source to form a platelet rich portion of the platelet source, and lysing the platelets in the platelet rich portion to form a plurality of lysates. An additional step includes lyophilizing the lysates to form lyophilized platelet lysates in a composition with released concentrations of available growth factors, cytokines, and chemokines. In one example, at 30%, by platelet count, of platelets from a platelet source can be lysed using this process.Type: GrantFiled: May 16, 2017Date of Patent: May 4, 2021Assignee: Jadi Cell LLCInventor: Amit Patel
-
Patent number: 10383833Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.Type: GrantFiled: October 9, 2017Date of Patent: August 20, 2019Assignee: Milanapharm LLCInventors: Hemant H Alur, James A H Harwick
-
Patent number: 10358627Abstract: Synthetic storage media are disclosed for use in the processing and the storing of platelets. The storage media includes a platelet storage solution and less than 20 percent plasma to preserve platelet function after at least 7 days of storage.Type: GrantFiled: August 18, 2014Date of Patent: July 23, 2019Assignee: FENWAL, INC.Inventors: Veronique Mayaudon, Jean-Marc Payrat
-
Patent number: 9867852Abstract: The invention relates to a viral inactivated biological liquid or dry mixture and to its preparation. Principally, the invention relates, but is not limited, to a mixture derived from a platelet source.Type: GrantFiled: December 19, 2013Date of Patent: January 16, 2018Assignee: Omrix Biopharmaceuticals Ltd.Inventors: Lior Weissman, Itai Podoler, Israel Nur, Tamara Byk-Tennenbaum
-
Patent number: 9759730Abstract: The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) antagonists with antithrombotic activity.Type: GrantFiled: October 8, 2014Date of Patent: September 12, 2017Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBHInventor: Andreas Rechner
-
Patent number: 9609861Abstract: The present invention relates to a platelet additive solution (PAS) having an amount of one or more ?-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.Type: GrantFiled: October 7, 2013Date of Patent: April 4, 2017Assignees: Velico Medical Inc., The Brigham and Women's Hospital, Inc.Inventors: Qiyong Peter Liu, Karin Hoffmeister, Robert Sackstein
-
Patent number: 9506938Abstract: A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.Type: GrantFiled: May 1, 2008Date of Patent: November 29, 2016Assignee: ACCUMETRICS, INC.Inventors: Barry Coller, Dennis Durbin
-
Patent number: 9173906Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial.Type: GrantFiled: February 10, 2014Date of Patent: November 3, 2015Assignee: Smith & Nephew, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Chevallay, Christopher Rinsch
-
Patent number: 9168281Abstract: Provided herein are compositions for treating wounds, method of making and using the system thereof. The system or kit for treating a wound includes a first composition having cetylpyridinium chloride, Aloe vera, and ascorbic acid for sanitizing a wound. The system or kit includes a second composition having concentrated platelet-rich plasma and a hypertonic saline solution for activating granulation of the wound. The system or kit includes a third composition having Aloe vera, ascorbic acid, vitamin A, vitamin E and immunoglobulins for initiating re-epithelialization of the wound.Type: GrantFiled: March 9, 2012Date of Patent: October 27, 2015Inventor: Charles E. Worden, Sr.
-
Patent number: 9095704Abstract: A method of mitigating the effect of bodily pathogens including providing a light applicator including a housing, a power supply, and at least one light source wherein the light source is configured to emit light in the ultraviolet range when energized by the power supply, and directing the applicator toward a bodily orifice so as to directly irradiate the orifice for a period of time.Type: GrantFiled: November 19, 2010Date of Patent: August 4, 2015Assignee: UV Technologies, LLCInventor: Kevin McGuire
-
Patent number: 9080141Abstract: The present invention is directed to a device for the growth of new bone or bone-like tissue under in vitro cell culture conditions.Type: GrantFiled: September 11, 2006Date of Patent: July 14, 2015Assignee: LifeNet HealthInventors: Lloyd Wolfinbarger, Xiaofei Qin
-
Patent number: 9034646Abstract: The invention concerns human platelet extracts rich in growth factors (PGF) for wound healing and stem cell expansion. Accordingly the subject invention relates to a virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF, which is preferably enriched in TGF, IGF and EGF-rich. The present invention further concerns a method for obtaining a platelet lysate comprising the steps of contacting a starting platelet concentrate with a solvent and/or a detergent, incubating the starting platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., optionally removing the solvent and/or the detergent by oil extraction and obtaining an aqueous protein phase, and incubating the solvent and/or detergent-treated platelet concentrate or the aqueous protein phase with charcoal.Type: GrantFiled: November 26, 2012Date of Patent: May 19, 2015Assignee: ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.Inventors: Thierry Burnouf, Cheng-Yao Su
-
Publication number: 20140377336Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.Type: ApplicationFiled: January 22, 2013Publication date: December 25, 2014Inventors: Dennis Brown, Jeffrey Bacha, Sandra Dunn
-
Publication number: 20140335195Abstract: The invention concerns a pharmaceutical composition comprising a platelet lysate and its use to treat a wound, an anal fissure, vaginal atrophy or a wrinkle.Type: ApplicationFiled: November 23, 2012Publication date: November 13, 2014Applicant: CELL THERAPY LIMITEDInventors: Thomas Averell Houze, Martin John Evans, Ajan Reginald, Ina Laura Pieper
-
Patent number: 8871199Abstract: Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.Type: GrantFiled: November 26, 2012Date of Patent: October 28, 2014Assignee: Regenerative Sciences, LLCInventor: Christopher J. Centeno
-
Publication number: 20140287014Abstract: This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.Type: ApplicationFiled: January 20, 2014Publication date: September 25, 2014Inventors: Timothy A. Ringeisen, William Christopher Wattengel
-
Patent number: 8821858Abstract: This invention relates to an improved Lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back bone), white blood cells with optional none, one or more additional anti-oxidant such as vitamin A and/or C and/or E, and/or none one or more antibiotics and/or GHK-Cu (produced by ProCyte Inc.Type: GrantFiled: March 26, 2008Date of Patent: September 2, 2014Assignee: GW IP, LLCInventors: James Bennie Gandy, Mackie J. Walker, Jr.
-
Publication number: 20140186455Abstract: An implant for promoting accelerated wound healing. The implant comprises a non-flocculating fiber material, admixed with a settable fluid. The fiber component typically will have short fiber lengths, so as to avoid forming entangled masses or clumps when mixed with a fluid. In an embodiment, the fiber material is native collagen fibers and the settable fluid is an isolated blood fraction, such as platelet rich plasma and platelet poor plasma. The native collagen fiber retaining the native crosslinks of the source tissue and providing an architectural and structural scaffolding for advancing cellular infiltration. The wound healing implant will accelerate the bodies healing process, to provide better healing and less scar tissue of the wound site.Type: ApplicationFiled: December 31, 2012Publication date: July 3, 2014Inventors: Gino Bradica, Ryan Saska, Christopher DiJiacomo, Timothy A. Ringeisen
-
Patent number: 8734854Abstract: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.Type: GrantFiled: July 9, 2009Date of Patent: May 27, 2014Inventors: James B. Gandy, Robert J. Brandt, Ryan N. Brandt, Clark Galen, Joseph F. Greco, John Kiwczak
-
Publication number: 20140127314Abstract: In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component. This disclosure also provides a method for preparing the composition, comprising the steps of (a) lysing platelets providing a lysate; (b) removing cell debris; and (c) depleting fibrinogen by forming a removable mass by adding a metal salt such as calcium chloride. Furthermore, the disclosure also describes the product produced using said method.Type: ApplicationFiled: June 26, 2012Publication date: May 8, 2014Applicants: CHILDREN'S HEATLHCARE OF ATLANTA, INC., EMORY UNIVERSITYInventors: Ian B. Copland, Jacques Galipeau
-
Publication number: 20140056989Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.Type: ApplicationFiled: November 5, 2013Publication date: February 27, 2014Applicant: Omrix Biopharmaceuticals Ltd.Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
-
Publication number: 20140037750Abstract: Automated systems and methods for providing platelet concentrates and synthetic storage media with reduced residual plasma volumes are disclosed. The disclosed systems and methods reduce the residual volume of plasma in platelet concentrate to obtain a platelet product having a volume of plasma that is approximately 5% or less of the total platelet product volume. The disclosed systems and methods also reduce the residual volume of plasma in platelet concentrate to obtain a washed platelet product, wherein the volume of plasma in the washed platelet product is approximately 1% or less of the total washed platelet product volume. Storage media for platelets including less than approximately 10% plasma are also disclosed.Type: ApplicationFiled: April 6, 2012Publication date: February 6, 2014Applicant: Fenwal, Inc.Inventors: Katherine Radwanski, Kyungyoon Min
-
Patent number: 8603821Abstract: A method for preparing serum and a serum preparation apparatus is provided that can give a large amount of serum with high culture efficiency regardless of freshness of blood used. In a method for preparing serum from blood containing at least platelets, a platelet processing step is provided in which platelet membrane in the blood is destroyed. After the platelet processing step, a deposition step for depositing thermolabile protein in blood and a removal step for removing the thermolabile protein, which has been deposited in the deposition step, are preferably provided.Type: GrantFiled: March 5, 2008Date of Patent: December 10, 2013Assignee: JMS Co., Ltd.Inventors: Koji Suzuki, Seishin Tanaka, Satoshi Hirai, Mari Takabatake
-
Patent number: 8603541Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.Type: GrantFiled: December 20, 2011Date of Patent: December 10, 2013Assignee: Omrix Biopharmaceuticals Ltd.Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
-
Publication number: 20130287753Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.Type: ApplicationFiled: June 28, 2013Publication date: October 31, 2013Inventor: Christopher J. Centeno
-
Patent number: 8529957Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides compositions comprising plasma or platelet-rich plasma alone or in combination with cell preparations for use in tissue regeneration and bone regeneration and pain reduction.Type: GrantFiled: August 21, 2007Date of Patent: September 10, 2013Inventors: Antoine Turzi, Donald Francois Du Toit
-
Publication number: 20130129816Abstract: A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.Type: ApplicationFiled: January 9, 2013Publication date: May 23, 2013Applicant: Abbott Cardiovascular Systems Inc.Inventor: Abbott Cardiovascular Systems Inc.
-
Publication number: 20130084341Abstract: Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.Type: ApplicationFiled: November 26, 2012Publication date: April 4, 2013Applicant: REGENERATIVE SCIENCES, LLCInventor: Regenerative Sciences, LLC
-
Patent number: 8409810Abstract: The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.Type: GrantFiled: November 17, 2006Date of Patent: April 2, 2013Assignee: Biogen Idec Ma Inc.Inventors: Yen-Ming Hsu, Lihe Su
-
Patent number: 8404256Abstract: This invention relates to a process to facilitate osteochondral bone remodeling in a subject by inducing regeneration of this bone to a healthy, vascularized state capable of supporting the underlying hyaline cartilage of articular joints and spinal discs, both biomechanically and metabolically and to deliver a bioactive agent. This process involves the steps of: administering an effective amount of an injectable in situ curing biomaterial composite to a site. The biomaterial composite product is prepared by a process involving the steps: admixing an alginate solution with a nonporous aggregate of ?-tricalcium phosphate, in a sufficient amount to initiate polymerization of the alginate solution, to form a hydrogel having from between 10 to 20 percent by volume of ?-tricalcium phosphate.Type: GrantFiled: May 2, 2012Date of Patent: March 26, 2013Assignee: The University of Memphis Research FoundationInventors: Jonathan Dempsey McCanless, Warren Ollver Haggard
-
Patent number: 8343518Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.Type: GrantFiled: October 12, 2011Date of Patent: January 1, 2013Assignee: MedImmune, LLCInventor: Vu Truong-Le
-
Publication number: 20120321722Abstract: The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment.Type: ApplicationFiled: May 17, 2012Publication date: December 20, 2012Inventors: Qiyong Peter Liu, Karin Hoffmeister
-
Publication number: 20120315338Abstract: The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion.Type: ApplicationFiled: December 3, 2010Publication date: December 13, 2012Applicant: Stem Cell & Regenerative Medicine International, Inc.Inventors: Feng Li, Shi-Jiang Lu
-
Publication number: 20120282302Abstract: This invention relates to a process to facilitate osteochondral bone remodeling in a subject by inducing regeneration of this bone to a healthy, vascularized state capable of supporting the underlying hyaline cartilage of articular joints and spinal discs, both biomechanically and metabolically and to deliver a bioactive agent. This process involves the steps of: administering an effective amount of an injectable in situ curing biomaterial composite to a site. The biomaterial composite product is prepared by a process involving the steps: admixing an alginate solution with a nonporous aggregate of ?-tricalcium phosphate, in a sufficient amount to initiate polymerization of the alginate solution, to form a hydrogel having from between 10 to 20 percent by volume of ?-tricalcium phosphate.Type: ApplicationFiled: May 2, 2012Publication date: November 8, 2012Inventors: Jonathan Dempsey McCanless, Warren Ollver Haggard
-
Patent number: 8303993Abstract: The present relates to an autologous bioadhesive sealant composition, or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. A platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. In one embodiment the platelet rich plasma is divided into two portions. In phase one, a compound that reverses the effect of the anticoagulant is added to the first portion and a clot is allowed to form. The clot is then triturated, and the resulting, serum containing autologous thrombin is collected. In phase two, the serum obtained from phase one is mixed with the second portion of the-platelet rich plasma to form the bioadhesive sealant of the invention.Type: GrantFiled: June 23, 2005Date of Patent: November 6, 2012Assignee: Ateriocyte Medical Systems, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
-
Patent number: 8282963Abstract: This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.Type: GrantFiled: October 15, 2008Date of Patent: October 9, 2012Assignee: The Regents of the University of Colorado, a body corporateInventor: Mark T. Roedersheimer
-
Patent number: 8268362Abstract: The invention relates to a medicinal product for topical use for the promotion of wound healing, which comprises thrombocytes or thrombocyte fragments, wherein the thrombocytes or thrombocyte fragments contain growth factors and are capable of releasing the same and are present in the lyophilized or deep-frozen state and have been subjected to a process for virus partitioning and/or virus inactivation.Type: GrantFiled: April 7, 2004Date of Patent: September 18, 2012Assignee: Bio-Products & Bio-Engineering AktiengesellschaftInventors: Friedrich Braun, Hans Peter Spängler, Johann Eibl
-
Publication number: 20120156306Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.Type: ApplicationFiled: December 20, 2011Publication date: June 21, 2012Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
-
Publication number: 20120114761Abstract: A skincare stimulant having an effective dose of platelets and pharmaceutically acceptable solvents and/or excipients, wherein the effective dose refers to the presence of at least 1000 platelets in every milligram of skincare stimulant.Type: ApplicationFiled: November 3, 2011Publication date: May 10, 2012Applicant: Central Medical Technologies Inc.Inventors: Chih I LIN, Han-Lei Wan
-
Patent number: 8168230Abstract: A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the steps of (a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation, (b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof.Type: GrantFiled: December 22, 2005Date of Patent: May 1, 2012Assignee: Advance Holdings LimitedInventor: Virgilio Evangelista
-
Publication number: 20120093941Abstract: Compositions and methods for preparing neutrophil-depleted platelet rich plasma are provided. Generally, these compositions comprise a higher concentration of platelets and depressed concentrations of neutrophils relative to whole blood although white blood cells may be at higher concentrations than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The neutrophil-depleted platelet rich plasma composition may be delivered in conjunction with reperfusion therapy.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Inventor: Allan Kumar Mishra
-
Patent number: 8137663Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: GrantFiled: March 26, 2009Date of Patent: March 20, 2012Assignee: Wellstat Biologics CorporationInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Patent number: 8124130Abstract: Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations of the present invention preferably include platelet-rich plasma with a pharmaceutical agent. The pharmaceutical agent may be a glucocorticoid hormone or other organic pharmaceutical agent. Particularly preferred pharmaceutical agents include dexamethasone, melatonin, purmorphamine, 17?-estradiol, vitamin K2 (menaquinone-4, MK4), bisphosphonates, derivatives thereof, and combinations thereof. The formulations of the present invention may be directly administered to a surgical or injury site where improved bone growth is desired. The formulations may also be applied to or otherwise incorporated into scaffolding structural components commonly employed in the medical field to promote bone structure and growth. The pharmaceutical agent may be employed in an immediate release form or a sustained release form.Type: GrantFiled: May 30, 2008Date of Patent: February 28, 2012Inventor: James Louis Rutkowski
-
Publication number: 20120027867Abstract: The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.Type: ApplicationFiled: April 6, 2010Publication date: February 2, 2012Applicant: ENTEGRION, INC.Inventors: Thomas H. Fischer, Joseph A. DaCorta, Michael Lawrence Galiger
-
Publication number: 20120016489Abstract: Implantable pliable bone blocks comprising a solid block of cortical bone characterized by a length, width and thickness, having a first and a second face on opposite sides of the block. The first and second faces have a plurality slot features. The angle of incidence of the slot features of the first face and the x-axis and the angle of incidence of the slot features of the second face and the x-axis (a2) are such that the slots would intersect if they were in the same plane. Methods are provided for making implantable pliable bone blocks.Type: ApplicationFiled: July 16, 2010Publication date: January 19, 2012Applicant: EBI, LLCInventor: Bradford J. COALE
-
Patent number: 8067017Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.Type: GrantFiled: October 29, 2007Date of Patent: November 29, 2011Assignee: MedImmune, LLCInventor: Vu Truong-Le
-
Publication number: 20110280952Abstract: The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described.Type: ApplicationFiled: May 31, 2011Publication date: November 17, 2011Applicants: BIOMED DEVICE S.R.L., UNIVERSITA' DEGLI STUDI DI PAVIAInventors: Carla Marcella Caramella, Maria Cristina Bonferoni, Silvia Stefania Rossi, Giuseppina Sandri, Franca Ferrari, Cesare Giuseppe Perotti, Claudia Del Fante